Q5168Temporary Codes
Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg
Short description: Inj. nufymco, 0.1 mg
- Effective date
- July 1, 2026
- Termination date
- —
Related codes (Q-series)
Q0035CardiokymographyQ0081Infusion ther other than cheQ0083Chemo by other than infusionQ0084Chemotherapy by infusionQ0085Chemo by both infusion and oQ0091Obtaining screen pap smearQ0092Set up port xray equipmentQ0111Wet mounts/ w preparationsQ0112Potassium hydroxide prepsQ0113Pinworm examinationsQ0114Fern testQ0115Post-coital mucous exam
Frequently asked questions
What is HCPCS code Q5168?
Q5168 is a HCPCS Level II code for Injection, ranibizumab-leyk (nufymco), biosimilar, 0.1 mg.
What category is HCPCS code Q5168 in?
Q5168 falls under the Temporary Codes category of HCPCS Level II.
When did HCPCS code Q5168 become effective?
Q5168 has been effective since July 1, 2026, per CMS's quarterly HCPCS update.
HCPCS Level II data from CMS (public domain). HCPCS Level I (CPT) codes are not included — CPT is copyrighted by the American Medical Association. Always verify codes with authoritative sources before making coding or billing decisions.